Inflation Reduction Act: A Game Changer for Cardiovascular Therapies Access

By Danélia Botes

September 29, 2023

First 10 Drugs Announced for Medicare Price Negotiation

On August 29, 2023, the Biden-Harris administration revealed the first 10 drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA). Five of these drugs treat cardiovascular conditions such as atrial fibrillation and heart failure. This is a significant step towards improving access to lifesaving therapies for cardiovascular conditions that affect millions of older US residents.

The rising prevalence of cardiovascular and metabolic diseases in the elderly (65 years and above) has been a significant factor in the development of new pharmaceutical treatments. This has also caused a shift in standard care practices, with the adoption of newer, costlier brand-name drugs in place of older, more affordable generics.

For example, the replacement of warfarin with direct oral anticoagulants (DOACs) for preventing stroke in atrial fibrillation patients is discussed. Warfarin comes at a mere $4 per month, whereas DOACs can cost between $378 to $566 monthly. This price difference has resulted in a nearly 17-fold surge in Medicare’s annual expenditure on oral anticoagulation therapy, from an estimated $440 million in 2011 to a whopping $7.4 billion in 2019.

This narrative is continued by examining the evolution of medical treatment guidelines for patients suffering from heart failure with reduced ejection fraction (HFrEF). The previous standard treatment comprised three affordable generic drugs: a β-blocker, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and a mineralocorticoid receptor antagonist. The current standard, however, includes sacubitril/valsartan and a sodium-glucose cotransporter-2 inhibitor. The cost disparity is significant. While the former regimen could cost as low as $10 a month, the current standard-of-care regimen can exceed $1200 a month.

Implications for Patients and Manufacturers

The IRA plans to address the issue of high medication costs by negotiating prices with drug manufacturers. They anticipate this negotiation will save the government $100 billion from 2026 to 2031. The lower negotiated price will also reduce out-of-pocket costs for patients. Additionally, the IRA will mandate all Part D plans to cover drugs with negotiated prices, improving access to these medications.

Reference url

Recent Posts

Effective management of diabetes
         

Effective Management of Diabetes in Arab Region: Insights and Strategies

🌍 Today is World Diabetes Day! Managing diabetes effectively is key to a healthier life! Discover strategies for preoperative risk assessment, obesity management, and safe fasting during Ramadan. Let’s prioritise our health together! 💪

#SyenzaNews #WorldDiabetesDay #DiabetesManagement #RamadanFasting #ObesityManagement

Cervical Cancer Screening
     

Improving Cervical Cancer Screening: HPV Self-Collection Tests

🌍 How can self-collection methods improve cervical cancer screening?

A recent article from the National Cancer Institute explores the groundbreaking FDA approval for HPV tests that allow patients to safely collect their own vaginal samples in a healthcare setting. This innovation promises to enhance access to screening for underserved populations and could transform the future of cervical cancer prevention. Jump into the details and learn how this initiative is poised to address health disparities in the U.S.

#SyenzaNews #oncology #HealthcareInnovation #HealthTech #innovation

AMR surveillance Africa
    

Strengthening AMR Surveillance in Africa

🌍 How can we combat the rising threat of Antimicrobial Resistance (AMR) in Africa?

The new guidance from Africa CDC presents a comprehensive framework for strengthening AMR surveillance. By implementing a One Health approach and enhancing collaboration, we can address the challenges posed by AMR and significantly improve public health outcomes across the continent.

Jump into the details of this critical initiative and discover how we can work together to forge a sustainable path forward!

#SyenzaNews #GlobalHealth #HealthcareInnovation #DataScience #AMR #OneHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.